1. |
American Society of Hospital Pharmacists. ASHP statement on the use of medications for unlabeled uses. Am J Hosp Pharm, 1992, 49(8): 2006-2008.
|
2. |
广东省药学会.药品未注册用法专家共识, 2010-03-18.
|
3. |
Beeh KM, Beier J, Esperester A, et al. Antiinflammatory propertiesof ambroxol. Eur J Med Res, 2008, 13(12): 557-562.
|
4. |
Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol, 2008, 4(8): 1119-1129.
|
5. |
Paleari D, Rossi GA, Nicolini G, et al. Ambroxol: a multifacetedmolecule with additional therapeutic potentials in respiratory disorders of childhood. Expert Opin Drug Discov, 2011, 6(11): 1203-1214.
|
6. |
周婧, 陈文颖, 劳海燕, 等.广东省人民医院2012年盐酸氨溴索注射剂超说明书用药情况调查.中国循证医学杂志, 2014, 14(9): 1030-1037.
|
7. |
Mészáros I, Mórocz J, Szlávi J, et al. Epidemiology and clinicopathology of aortic dissection. Chest, 2000, 117(5): 1271-1278.
|
8. |
Hiratzka LF, Bakris GL, Beckman JA, et al. guidelines for the diagnosis and management of patients with Thoracic Aortic Disease. J Am CollCardiol, 2010, 55(14): e27-e129.
|
9. |
Krahenbuhl ES, Immer FF, Stalder M, et al. Technical advances improved outcome in patients undergoing surgery of the ascending aorta and/or aortic arch: Ten years, experience. Eur J CardiothoracSurg, 2008, 34(3): 595-599.
|
10. |
周婧, 陈文颖, 杨敏.盐酸氨溴索对Stanford A型主动脉夹层急诊手术后的肺保护作用.中国医院药学杂志, 2014, 34(23): 66-70.
|
11. |
中国医师协会胸外科医师分会, "胸外科围手术期肺部并发症"研讨会.胸外科围手术期肺部并发症防治专家共识.中华胸心血管外科杂志, 2009, 25(4): 217-218.
|
12. |
陈渊, 马彬, 杨克虎, 等.围手术期使用盐酸氨溴索对肺保护作用的系统评价.中国循证医学杂志, 2009, 9(5): 558-564.
|
13. |
Wang S, Huang D, Ma Q, et al. Does ambroxol confer a protective effect on the lungs in patients undergoing cardiac surgery or having lung resection? Interact Cardiovasc Thorac Surg, 2014, 18(6):830-834.
|
14. |
Wang X, Wang L, Wang H, et al. Perioperative Lung Protection Provided by High-Dose Ambroxol in Patients with Lung Cancer. Cell Biochem Biophys, 2015, 73(2): 281-284.
|
15. |
Assessment report as adopted by the PRAC and considered by the CMDh with all information of a commercially confidential nature deleted: Ambroxol and bromhexine containing medicinal products. 2015.
|
16. |
McAlister FA, Bertsch K, Man J, et al. Incidence of and risk factors for pulmonary complications after nonthoracic surgery. Am J Respir Crit Care Med, 2005, 171(5): 514.
|
17. |
Canet J, Gallart L, Gomar C, et al. Prediction of Postoperative Pulmonary Complications in a Population-based Surgical Cohort. Anesthesiology, 2010, 113(6): 1338-1350.
|
18. |
Qaseem A, Snow V, Fitterman N, et al. Risk Assessment for and Strategies To Reduce Perioperative Pulmonary complications for patients undergoing noncardiothoracic surgery: a guideline from the American college of physicians. Ann Intern Med, 2006, 144(8): 575-580.
|
19. |
劳海燕, 王启仪, 杨敏, 等.广东省人民医院超说明书用药临床管理方法与流程研究.中国循证医学杂志, 2014, 14(9): 1025-1029.
|